Rigel Pharmaceuticals (RIGL) Cash from Operations Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Rigel Pharmaceuticals | 551.62 Mn | 404.94 Mn | 54.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 16.40% |
| Dec 31, 2025 | 27.82% |
| Sep 30, 2025 | 26.45% |
| Jun 30, 2025 | 33.09% |
| Mar 31, 2025 | 22.00% |
| Dec 31, 2024 | 28.50% |
| Sep 30, 2024 | 28.33% |
| Jun 30, 2024 | 15.08% |
| Mar 31, 2024 | -54.52% |
| Dec 31, 2023 | -20.46% |
| Sep 30, 2023 | 41.64% |
| Jun 30, 2023 | 17.29% |
| Mar 31, 2023 | 29.50% |
| Dec 31, 2022 | -2.13% |
| Sep 30, 2022 | 5.46% |
| Jun 30, 2022 | 7.89% |
| Mar 31, 2022 | -4.31% |
| Dec 31, 2021 | -8.90% |
| Sep 30, 2021 | 14.53% |
| Jun 30, 2021 | 37.95% |
| Mar 31, 2021 | 2.30% |
| Dec 31, 2020 | -2.45% |
| Sep 30, 2020 | -15.55% |
| Jun 30, 2020 | 5.00% |
| Mar 31, 2020 | -16.78% |
| Dec 31, 2019 | 8.45% |
| Sep 30, 2019 | 4.44% |
| Jun 30, 2019 | 3.54% |
| Mar 31, 2019 | 48.96% |
| Dec 31, 2018 | 21.21% |
| Sep 30, 2018 | 0.65% |
| Jun 30, 2018 | -4.83% |
| Mar 31, 2018 | 1.41% |
| Dec 31, 2017 | 1.78% |
| Sep 30, 2017 | 2.14% |
| Jun 30, 2017 | 1.26% |
| Mar 31, 2017 | 2.26% |
| Dec 31, 2016 | 7.75% |
| Sep 30, 2016 | -12.03% |
| Jun 30, 2016 | -1.44% |
| Mar 31, 2016 | -1.55% |
| Dec 31, 2015 | -27.30% |
| Sep 30, 2015 | 13.03% |